An open, parallel group study comparing a frusemide/amiloride diuretic and a diuretic containing cyclopenthiazide

Related Experiment Video

Updated: Aug 18, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

S Allman1, R J Norris

  • 1Rorer Health Care Ltd, Eastbourne, East Sussex, UK.

The Journal of International Medical Research
|January 1, 1990
PubMed

Insights

Frusemide/amiloride and cyclopenthiazide/potassium effectively treated cardiac failure symptoms. Frusemide/amiloride demonstrated comparable efficacy with fewer dose adjustments in this 12-week study.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Congestive heart failure (CHF) management often requires diuretic therapy.
  • Balancing efficacy and safety in diuretic treatment is crucial for patient outcomes.

Purpose of the Study:

  • To compare the efficacy and tolerability of frusemide/amiloride versus cyclopenthiazide/potassium in patients with cardiac failure.
  • To assess the need for dose adjustments and identify any drug-related adverse effects.

Main Methods:

  • A randomized trial involving 71 patients with cardiac failure requiring diuretic treatment.
  • Patients received either frusemide/amiloride or cyclopenthiazide/potassium daily for 12 weeks.
  • Clinical symptoms, patient self-assessments, plasma potassium, and laboratory data were monitored.

Main Results:

  • Both treatments significantly improved symptoms of cardiac failure, including crepitations, oedema, and dyspnoea, with no significant differences between groups.
  • A higher percentage of patients on cyclopenthiazide/potassium required dose doubling (47%) compared to frusemide/amiloride (30%).
  • Plasma potassium levels remained unaffected, and no significant laboratory changes were observed. Withdrawal rates due to potential drug-related effects were slightly higher in the cyclopenthiazide/potassium group.

Conclusions:

  • Frusemide/amiloride is an efficacious and acceptable treatment option for congestive heart failure.
  • The combination of frusemide/amiloride offers a viable alternative with potentially fewer dose adjustments compared to cyclopenthiazide/potassium.

More Related Videos

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol07:59

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Published on: July 28, 2018

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...